12/24
10:00 am
amlx
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
12/22
10:00 am
amlx
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
12/18
10:00 am
amlx
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
12/15
10:00 am
amlx
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
Low
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
12/11
02:00 pm
amlx
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect
Low
Report
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect
12/5
08:01 am
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/4
07:31 am
amlx
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia [Yahoo! Finance]
Medium
Report
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia [Yahoo! Finance]
12/4
07:30 am
amlx
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Low
Report
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
11/27
09:05 am
amlx
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference [Yahoo! Finance]
Low
Report
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference [Yahoo! Finance]
11/27
09:00 am
amlx
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
Low
Report
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
11/25
02:42 pm
amlx
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along [Seeking Alpha]
Low
Report
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along [Seeking Alpha]
11/19
06:20 am
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Low
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
11/18
08:06 am
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $11.00 price target on the stock, up previously from $3.00.
Medium
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $11.00 price target on the stock, up previously from $3.00.
11/9
10:22 am
amlx
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) [Yahoo! Finance]
Medium
Report
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) [Yahoo! Finance]
11/8
02:21 am
amlx
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/7
07:00 am
amlx
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Medium
Report
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
11/4
09:00 am
amlx
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Low
Report
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
10/23
07:09 am
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.
Low
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.
10/18
03:32 pm
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.
Medium
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.
10/18
08:33 am
amlx
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
10/18
07:39 am
amlx
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week [Yahoo! Finance]
High
Report
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week [Yahoo! Finance]
10/17
09:50 am
amlx
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial [Seeking Alpha]
Low
Report
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial [Seeking Alpha]
10/17
09:00 am
amlx
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
High
Report
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
10/15
09:00 am
amlx
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
Medium
Report
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
10/3
03:06 pm
amlx
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm